What this means
This trial is looking at how long filters last during continuous dialysis in intensive care. It has not posted results yet, so it cannot tell us the answer.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 5 sites
The science
- Registered title
- Filter Lifespan in Continuous Renal Replacement Therapy
- Trial ID
- NCT05450185 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Critically Ill, Continuous Renal Replacement Therapy, Infections
- What is tested
- Critically ill patients with continuous renal replacement therapy
- Sponsor
- University Hospital Muenster
- Ages
- 18 Years to no maximum
- Dates
- First posted Jul 8, 2022 · updated Dec 12, 2024
Registry summary
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
Sites (5)
- Univ.-Klinik Innsbruck, Innsbruck, Austria
- Universidade de São Paulo, São Paulo, Brazil
- Universitätsklinikum Erlangen-Nürnberg, Abteilung für Nephrologie und Hypertensiologie, Erlangen, Germany
- Kliniken Maria Hilf, Klinik für Anästhesiologie und Operative Intensivmedizin, Mönchengladbach, Germany
- University Hospital Muenster, Münster, Germany